Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014.

Adverse Reactions After Intravenous Iron Infusion Among Inflammatory Bowel Disease Patients in the United States, 2010-2014. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Akhuemonkhan E, Parian A, Carson KA, Hutfless S Abstract Background: Anemia is a frequent complication of Crohn’s disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD). Intravenous (IV) iron is recommended as the initial therapy for patients with clinically active IBD, severe anemia, and intolerance to oral iron. IV iron is associated with serious adverse effects including a black box warning for anaphylaxis…

Read More

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards.

Cancer-Associated Chemotherapy Induces Less IBD Exacerbations and a Reduction of IBD Medication Afterwards. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Koc ÖM, van Kampen RJW, van Bodegraven AA Abstract Background: The prevalence of inflammatory bowel disease (IBD) is increasing and, consequently, more IBD patients will develop cancer with need for cancer-associated chemotherapy. Physicians are therefore confronted with whether they should continue, stop, or restart IBD medication in relation with chemotherapy. The current strategy in our hospital is to discontinue immunomodulating IBD medication, comprising corticosteroids, anti-tumour necrosis factor (anti-TNF), and other…

Read More

The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort.

The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, Zimmerli L, Vavricka SR, Rogler G, Scharl M, Swiss IBD Cohort Study Group Abstract Background andAims: Vitamin and iron deficiencies are common in patients with inflammatory bowel disease (IBD) as a result of chronic intestinal inflammation, increase in demand, or dietary restrictions. Here, we assessed the frequency of complications in relation…

Read More

Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness.

Methotrexate and Thioguanine Rescue Therapy for Conventional Thiopurine Failing Ulcerative Colitis Patients: A Multi-center Database Study on Tolerability and Effectiveness. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Meijer B, Mulder CJJ, Bouma G, Ponsioen CY, van der Woude CJ, van der Meulen AE, Wintjens DSJ, Dijkstra G, Hoentjen F, Oldenburg B, van Bodegraven AA, de Boer NKH, Dutch Initiative on Crohn and Colitis (ICC) and Parelsnoer Institute Abstract Background: Patients with active ulcerative colitis (UC) failing conventional therapies are in need of rescue strategies. Due to the fact that accepted…

Read More

Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn’s Disease.

Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFα Treatment for Crohn’s Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Gamo K, Okuzono Y, Yabuki M, Ochi T, Sugimura K, Sato Y, Sagara M, Hayashi H, Ishimura Y, Nishimoto Y, Murakawa Y, Shiokawa Z, Gotoh M, Miyazaki T, Ebisuno Y Abstract Background: Anti-tumor necrosis factor alpha (anti-TNFα) therapy has become the mainstay of therapy for Crohn’s disease (CD). However, post-therapy, the recurrence rate is still high. The aim of this study was to dissect the…

Read More

Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis.

Combined Infection of Human Herpes Viruses: A Risk Factor for Subsequent Colectomy in Ulcerative Colitis. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Hosomi S, Watanabe K, Nishida Y, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe T, Nagahara H, Maeda K, Fujiwara Y Abstract Background: Little is known about the prevalence and pathogenicity of human herpes viruses except for cytomegalovirus (CMV) in patients with inflammatory bowel disease (IBD). The aim of this study was to determine the prevalence of…

Read More

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Van de Vondel S, Baert F, Reenaers C, Vanden Branden S, Amininejad L, Dewint P, Van Moerkercke W, Rahier JF, Hindryckx P, Bossuyt P, Ferrante M, Belgian IBD Research and Development (BIRD) Abstract Background: Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required…

Read More

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease.

The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Bernstein CN, Zhang L, Lix LM, Graff LA, Walker JR, Fisk JD, Patten SB, Hitchon CA, Bolton JM, Sareen J, El-Gabalawy R, Marriott J, Marrie RA, CIHR Team in Defining the Burden and Managing the Effects of Immune-mediated Inflammatory Disease Abstract Background: We evaluated the validity and reliability of multiple symptom scales for depression and anxiety for persons with inflammatory bowel disease (IBD). Methods: IBD participants in…

Read More

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. Inflamm Bowel Dis. 2018 Apr 12;: Authors: Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA Abstract Background: Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only a partial response. In these patients, a combination of anti-TNF-α and vedolizumab (VDZ) may act as a bridge until the full VDZ effect occurs. At present, clinical data on combination treatment with anti-TNF-α and VDZ are not available.…

Read More

Dysplasia in Inflammatory Bowel Disease: Historical Review, Critical Histopathological Analysis, and Clinical Implications.

Dysplasia in Inflammatory Bowel Disease: Historical Review, Critical Histopathological Analysis, and Clinical Implications. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Mark-Christensen A, Laurberg S, Haboubi N Abstract Colorectal cancer is the most serious complication of chronic inflammatory bowel disease. It is generally accepted that dysplasia in most cases precedes the development of colorectal cancer. Thus, detection of dysplasia through surveillance may allow therapeutic interventions to lower the risk of cancer. Our understanding of dysplasia has evolved over the past decades and guided rational decision-making, but many questions remain unanswered. We…

Read More
<< Go Back